IMR Press / FBL / Volume 14 / Issue 3 / DOI: 10.2741/3291

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Peroxisome proliferator-activated receptors and renal diseases
Show Less
1 Department of Physiology and Pathophysiology, Peking (Beijing) University Diabetes Center, Key Laboratory of Molecular Cardiovascular Science, Peking (Beijing) University Health Science Center, Beijing, China
Front. Biosci. (Landmark Ed) 2009, 14(3), 995–1009;
Published: 1 January 2009

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of ligand-dependent transcription factors. Three isoforms of PPAR, i.e., PPAR-α, -δ, and -γ, have been identified and are differentially expressed in various tissues, including the kidney. The target genes of PPARs are involved in diverse biological processes, including adipogenesis, lipid metabolism, insulin sensitivity, inflammatory response, reproduction, and cell growth and differentiation. PPARs have been reported to protect against renal injury through indirect systemic effects and/or direct renal effects in diabetic nephropathy, glomerulonephritis, renal cell carcinoma, acute renal failure and chronic renal disease. In this review, we summarize the role of the three identified PPAR isoforms, PPARα, -δ, and -γ, in renal physiology and discuss the renoprotective effects of PPAR ligands in various kidney diseases.

Back to top